For full functionality of this page it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser Pharmaceutical Industry Category Archives
US Flag
UK Flag Canada Flag

Category: Pharmaceutical Industry

Nov
13

Product Recalls Stabilize, But an Upsurge is Expected

While U.S. product recalls were relatively flat from the second to third quarter, expect an upsurge in the weeks and months to come as regulators – under growing pressure from Congress and consumer groups – turn their attention to currently unregulated categories.  Part of that pressure on regulators is a result of past handling of product safety issues.

Continue Reading
Nov
07

It’s Official: Active Pharmaceutical Ingredient Makers in FDA’s Crosshairs

If there was any doubt whether the entire active pharmaceutical ingredient (API) industry is a target for continued FDA scrutiny, it should be gone. Donald Ashley, director of FDA’s Office of Compliance, talked about major concerns the agency has with the API industry at the Association for Accessible Medicines’ conference. As reported in an

Continue Reading
Oct
22

Cannabis Recalled Without Federal Regulation

The product recall by Denver-based marijuana cultivator Bonsai Cultivation reminds us all of the unique regulatory dynamic facing the cannabis industry. In this case, the cultivator – working with state officials – pulled marijuana products off the market because they may contain elevated yeast and mold counts. The recall followed a Denver Department of Public Health & Environment examination of dried marijuana samples.

Continue Reading
Oct
09

FDA’s Recall Planning Guidance Offers Little New Insight

FDA started issuing draft industry guidance related to Hazard Analysis and Risk-Based Preventive Controls for Human Food (PCHF) in January 2018, but the 16 chapters are still a work in progress. Most recently, the FDA alerted the industry in the federal register that Chapter 14: Recall Plan is now available. The PCHF guidance specifies that companies and organizations “must establish a written recall plan for food that requires a preventive control (21 CFR 117.139(a)).

Continue Reading
Sep
25

Investigation Underway, Generic Zantac Shipments Stopped. Recall Next? Almost Undoubtedly

Bloomberg News recently published a lengthy piece on how carcinogens are allegedly infiltrating the generic drug supply in the United States. The very next day, drug safety officials announced that they were investigating whether Zantac and its generic counterparts contain levels of the probable carcinogen N-Nitrosodimethylamine, or NDMA – the same chemical that was found in blood-pressure pills last year. Those pills were ultimately recalled, and those

Continue Reading